Achieve Life Sciences Inc (ACHV) Stock Price, Quote & News

Company Profile

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothel...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 210 2217

Website: www.achievelifesciences.com

Address:

22722 29th Dr. SE, Suite 100, Bothell, United States

Willdowdell Jun. 4 at 5:35 PM

$ACHV the action on this doesn’t make sense for a stock that is staring at a cRL, even if it’s priced in.. could there be news coming on vaping earlier than expected?

1 · Reply

DMaulST Jun. 4 at 3:31 PM

$ACHV

0 · Reply

Merlintrader Jun. 4 at 12:29 PM

$ACHV $ARQT $VRDN JUNE PDUFA Watchlist: Small and Mid-Cap Biotech Catalysts Beyond Big Pharma https://www.merlintrader.com/june-pdufa-watchlist/

0 · Reply

CapitalMonk Jun. 3 at 4:16 PM

$ACHV Price: $4.82 (-4.17%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±4.03% RSI: 32.3 | Momentum: Strong Downside Volume: -43.9% vs avg Volatility: 5.79% Support: $4.41 | Resistance: $6.15 Data and analytics sourced from Given Analytics educational research: https://www.givenanalytics.com/

0 · Reply

markwall Jun. 3 at 12:19 PM

$ACHV So FDA is going to release their decision on a Saturday? So no market reaction on June 20.

1 · Reply

Sieppo Jun. 2 at 3:16 PM

$ACHV the CING stock first cratered over 20% on news, probably algos selling or something, then went up hard to +30% probably because the float is so low and retail buys and holds heavily and this was affirmation, derisking and a small delay for them. Cing likely needs near term dilution to stay afloat.

1 · Reply

Sieppo Jun. 2 at 1:12 PM

$ACHV Dunno why they want to market this 😂. They hired a dilution expert? But of course building a sales force etc is going to be expensive and I have a predicted another offering in 2027.. "Dr. Waldman is the Founder and Chief Executive Officer of Veradermics, Incorporated (NYSE: MANE), a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss. Veradermics completed an upsized initial public offering in February 2026 of approximately $294.8 million of gross proceeds, and subsequently raised an additional $472 million of gross proceeds in a follow-on offering and private placement in May 2026."

3 · Reply

Sieppo Jun. 2 at 1:11 PM

$ACHV Dunno why they want to market this 😂. But of course building a sales force etc is going to be expensive.. "Dr. Waldman is the Founder and Chief Executive Officer of Veradermics, Incorporated (NYSE: MANE), a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss. Veradermics completed an upsized initial public offering in February 2026 of approximately $294.8 million of gross proceeds, and subsequently raised an additional $472 million of gross proceeds in a follow-on offering and private placement in May 2026."

0 · Reply

InquisitorD Jun. 2 at 12:51 PM

$ACHV We are fortunate to have them on our team as we approach cytisinicline’s NDA resubmission and prepare for what comes next.” https://ir.achievelifesciences.com/news-events/press-releases/detail/263/achieve-life-sciences-appoints-jeffrey-farrow-and-reid-waldman-md-to-board-of-directors

0 · Reply

Sieppo Jun. 2 at 12:32 PM

$ACHV Cing received a manufacturing CRL today. It was somewhat expected but not clearly announced by the company like in Achieves case. The stock was already down a lot but you might see what kind of reactions those give.

0 · Reply

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

May 29, 2026, 8:00 AM EDT - 6 days ago

Achieve Life Sciences Proxy statement: Proxy filing

May 19, 2026, 2:15 PM EDT - 16 days ago

Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

2026-05-12T21:31:08.000Z - 23 days ago

Achieve Life Sciences files prospectus for resale of shares by holders

May 12, 2026, 8:30 AM EDT - 23 days ago

Achieve Life Sciences Earnings Call Transcript: Q1 2026

May 12, 2026, 8:30 AM EDT - 23 days ago

Achieve Life Sciences Earnings release: Q1 2026

May 12, 2026, 8:30 AM EDT - 23 days ago

Achieve Life Sciences Quarterly report: Q1 2026

May 12, 2026, 8:00 AM EDT - 23 days ago

Achieve Life Sciences Registration statement: Registration filing

2026-05-12T11:58:27.000Z - 23 days ago

Achieve Life Sciences reports Q1 EPS (19c), consensus (30c)

May 12, 2026, 7:05 AM EDT - 23 days ago

Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

May 12, 2026, 7:00 AM EDT - 23 days ago

Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates

May 5, 2026, 8:30 AM EDT - 4 weeks ago

Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026

May 1, 2026, 7:00 AM EDT - 4 weeks ago

Achieve Life Sciences Slides: Corporate presentation

2026-04-21T09:20:14.000Z - 6 weeks ago

Achieve Life Sciences initiated with a Buy at Canaccord

2026-04-20T20:46:40.000Z - 6 weeks ago

Achieve Life Sciences initiated with a Buy at Canaccord

2026-04-16T15:25:18.000Z - 7 weeks ago

Achieve Life Sciences announces $354M private placement

2026-04-16T14:03:48.000Z - 7 weeks ago

Achieve Life Sciences appoints Goldberg as CEO, names two leaders to board

Apr 16, 2026, 8:57 AM EDT - 7 weeks ago

Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors

Apr 16, 2026, 8:53 AM EDT - 7 weeks ago

Achieve Life Sciences Announces Up to $354 Million Private Placement

Apr 15, 2026, 8:00 AM EDT - 7 weeks ago

Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions

Mar 26, 2026, 8:30 AM EDT - 2 months ago

Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability

Mar 24, 2026, 2:23 PM EDT - 2 months ago

Achieve Life Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 24, 2026, 8:30 AM EDT - 2 months ago

Achieve Life Sciences Earnings Call Transcript: Q4 2025

Mar 24, 2026, 8:30 AM EDT - 2 months ago

Achieve Life Sciences Annual report: Q4 2025

Mar 24, 2026, 8:30 AM EDT - 2 months ago

Achieve Life Sciences Earnings release: Q4 2025

2026-03-24T11:10:44.000Z - 2 months ago

Achieve Life Sciences reports Q4 EPS (28c), consensus (28c)

Mar 24, 2026, 7:00 AM EDT - 2 months ago

Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 17, 2026, 8:30 AM EDT - 2 months ago

Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026

2026-03-09T20:45:55.000Z - 3 months ago

Aeon Biopharma appoints John Bencich as CFO

AEON

2026-03-04T13:21:27.000Z - 3 months ago

Achieve Life Sciences announces new data on cytisinicline to be presented

Mar 4, 2026, 8:00 AM EST - 3 months ago

Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study

2026-02-06T16:15:23.000Z - 4 months ago

H.C. Wainwright says Chantix news ‘significant win’ for Achieve Life Sciences

PFE

Jan 30, 2026, 4:05 PM EST - 4 months ago

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

2026-01-23T21:10:26.000Z - 4 months ago

Achieve Life Sciences files $300M mixed securities shelf

Jan 23, 2026, 7:00 AM EST - 4 months ago

Achieve Life Sciences Registration statement: Registration Filing

2026-01-12T13:55:17.000Z - 5 months ago

Achieve Life Sciences confirms promotion of Mark Rubinstein to CMO

Jan 12, 2026, 8:47 AM EST - 5 months ago

Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer

Jan 12, 2026, 7:00 AM EST - 5 months ago

Achieve Life Sciences Slides: Corporate presentation

2026-01-05T16:45:30.000Z - 5 months ago

H.C. Wainwright names two best 2026 ideas in SMID-cap biopharma

CNTB

2025-12-30T16:10:10.000Z - 5 months ago

Achieve Life near FDA approval of smoking addiction treatment, Hunterbrook says

Dec 17, 2025, 4:11 PM EST - 6 months ago

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

2025-11-25T09:45:19.000Z - 6 months ago

Achieve Life Sciences initiated with an Outperform at Citizens JMP

Nov 6, 2025, 8:30 AM EST - 7 months ago

Achieve Life Sciences Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 7 months ago

Achieve Life Sciences Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 7 months ago

Achieve Life Sciences Earnings release: Q3 2025

2025-11-06T12:05:50.000Z - 7 months ago

Achieve Life Sciences reports Q3 EPS (28c), consensus (26c)

Nov 6, 2025, 7:00 AM EST - 7 months ago

Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Nov 5, 2025, 7:00 AM EST - 7 months ago

Achieve Life Sciences Slides: Corporate Presentation

Nov 3, 2025, 8:30 AM EST - 7 months ago

Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

Oct 29, 2025, 8:30 AM EDT - 7 months ago

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025

Oct 20, 2025, 8:30 AM EDT - 8 months ago

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

Oct 17, 2025, 7:30 AM EDT - 8 months ago

Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation

Oct 2, 2025, 4:01 PM EDT - 8 months ago

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

Sep 22, 2025, 8:30 AM EDT - 9 months ago

Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline's Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD

Sep 18, 2025, 8:30 AM EDT - 9 months ago

Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer

Sep 11, 2025, 5:01 PM EDT - 9 months ago

Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer

Sep 8, 2025, 11:00 AM EDT - 9 months ago

Achieve Life Sciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 9 months ago

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

Sep 2, 2025, 8:30 AM EDT - 9 months ago

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

Aug 7, 2025, 8:30 AM EDT - 10 months ago

Achieve Life Sciences Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 10 months ago

Achieve Life Sciences Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 10 months ago

Achieve Life Sciences Earnings release: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 10 months ago

Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Aug 6, 2025, 6:00 PM EDT - 10 months ago

Achieve Life Sciences Slides: Corporate Presentation

Jul 29, 2025, 8:30 AM EDT - 11 months ago

Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 11 months ago

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025

Jul 22, 2025, 8:00 AM EDT - 11 months ago

Achieve Life Sciences Slides: Corporate Presentation

Jun 30, 2025, 7:52 PM EDT - 1 year ago

Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities

Jun 26, 2025, 11:43 PM EDT - 1 year ago

Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering

Jun 26, 2025, 4:03 PM EDT - 1 year ago

Achieve Life Sciences Announces Proposed Underwritten Public Offering

Jun 26, 2025, 4:02 PM EDT - 1 year ago

Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

OMC

Jun 4, 2025, 5:30 PM EDT - 1 year ago

Achieve Life Sciences Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake

May 13, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Earnings Call Transcript: Q1 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Quarterly report: Q1 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Earnings release: Q1 2025

May 13, 2025, 7:30 AM EDT - 1 year ago

Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

May 6, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Achieve Life Sciences Proxy statement: Proxy Filing

Apr 21, 2025, 11:19 AM EDT - 1 year ago

Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine

Mar 12, 2025, 11:30 AM EDT - 1 year ago

Achieve Life Sciences Transcript: Barclays 27th Annual Global Healthcare Conference 2025

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Earnings Call Transcript: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Annual report: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Earnings release: Q4 2024

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

Mar 7, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference

Mar 6, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025

Feb 11, 2025, 10:00 AM EST - 1 year ago

Achieve Life Sciences Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference

Feb 10, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

Jan 10, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

Jan 7, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

Dec 9, 2024, 8:30 AM EST - 1 year ago

Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

Dec 3, 2024, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

Nov 25, 2024, 7:54 AM EST - 1 year ago

Smoking Cessation Pipeline Insight 2024, with Focus on Emerging Drugs Cytisinicline (Achieve Life Sciences), EMB-001(Embera Pharmaceuticals) and SBP-9330 (Camino Pharma)

Nov 7, 2024, 4:30 PM EST - 1 year ago

Achieve Life Sciences Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Achieve Life Sciences Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Achieve Life Sciences Earnings release: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Achieve Life Sciences Registration statement: Registration Filing

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Achieve Life Sciences President and CMO, Dr. Cindy Jacobs, Speaks at FDA and NIH Smoking Cessation Public Meeting

Willdowdell Jun. 4 at 5:35 PM

$ACHV the action on this doesn’t make sense for a stock that is staring at a cRL, even if it’s priced in.. could there be news coming on vaping earlier than expected?

1 · Reply

DMaulST Jun. 4 at 3:31 PM

$ACHV

0 · Reply

Merlintrader Jun. 4 at 12:29 PM

$ACHV $ARQT $VRDN JUNE PDUFA Watchlist: Small and Mid-Cap Biotech Catalysts Beyond Big Pharma https://www.merlintrader.com/june-pdufa-watchlist/

0 · Reply

CapitalMonk Jun. 3 at 4:16 PM

0 · Reply

markwall Jun. 3 at 12:19 PM

$ACHV So FDA is going to release their decision on a Saturday? So no market reaction on June 20.

1 · Reply

Sieppo Jun. 2 at 3:16 PM

1 · Reply

Sieppo Jun. 2 at 1:12 PM

3 · Reply

Sieppo Jun. 2 at 1:11 PM

0 · Reply

InquisitorD Jun. 2 at 12:51 PM

0 · Reply

Sieppo Jun. 2 at 12:32 PM

0 · Reply

kuboss Jun. 1 at 7:38 PM

$ACHV Trump claims experimental drug revived terminally ill patients https://www.msn.com/en-au/news/insight/trump-claims-experimental-drug-revived-terminally-ill-patients/gm-GM1E9B5142?gemSnapshotKey=GM1E9B5142-snapshot-8&uxmode=ruby It sounds fantastic, of course, but he is speaking figuratively, so this announcement could be for us too.😉

0 · Reply

saulveable Jun. 1 at 2:46 PM

$ACHV no brainer

0 · Reply

ISimplyHaveNoIdea May. 30 at 4:22 PM

$ACHV I’ve got a nice 10k set aside for the post June rejection and brief dump. This will be on the market next year and will 5-10x from 4 dollars. If I was already in it I’d hold but loads won’t and I’m happy to pick those cheap ones up…

2 · Reply

Ghostrider2020 May. 29 at 7:43 PM

$ACHV Achieve Life Sciences (NASDAQ: ACHV) is officially set to join the Russell 3000® and Russell 2000® Indexes for the 2026 reconstitution cycle. Here is what you need to know about the inclusion: Effective Date: The addition will officially take effect at the opening of the U.S. equity markets on Monday, June 29, 2026 (following the final market close of the reconstitution period on June 26). Preliminary Lists: Achieve Life Sciences was named on the preliminary additions list published by FTSE Russell on May 22, 2026. What it Means: Membership in the Russell 3000 automatically grants inclusion into the small-cap Russell 2000. This inclusion typically broadens a company's institutional investor base and triggers automatic purchasing by index-tracking funds.

0 · Reply

Supermoto87 May. 29 at 12:38 AM

$ACHV Got all excited thinking they were going to earn us some extra interest tendies loaning out the fortune they just raised. Too bad Webull tagged the wrong Achieve: https://www.prnewswire.com/news-releases/achieve-appoints-veteran-banking-executive-john-davis-as-chief-credit-officer-302784610.html

1 · Reply

mhbrown24 May. 28 at 7:02 PM

$ACHV https://empor.top/us/ACHV

2 · Reply

Sieppo May. 28 at 5:55 PM

$ACHV Nice catch with the Russell 2000 add! This all must be funds forced to buy the stock now. Plenty of other indexes also to come in the future.

3 · Reply

MasterChiefCov May. 28 at 2:25 PM

$ACHV good time to top up?

1 · Reply

Deeconomics May. 28 at 11:47 AM

$ACHV Cytisinicline + FDA Commissioner's National Priority Voucher (CNPV) for vaping merits spotlight and public health support 👌 https://www.reuters.com/legal/litigation/big-tobacco-comes-out-top-after-us-fda-shake-up-2026-05-26/

0 · Reply

BG_BULL May. 23 at 9:40 AM

$ACHV We just entered Russell 2000! By the end of June, passive funds will buy between 6 and 12 million shares. They will take away a large part of the free ones for long-term holding. It will be interesting 😎

2 · Reply

BPharmCatalyst May. 22 at 4:17 PM

🚨 Key PDUFA dates left for the quarter: 🔹 $CING: May 31 PDUFA (ADHD / CMC Manufacturing focus) 🔹 $ACHV: June 20 PDUFA (Smoking Cessation / Disruptive Potential) 🔹 $UNCY: June 29 PDUFA (Kidney Disease / Class 2 Review) 📺Watch our short: https://youtube.com/shorts/cS_8wTZIoSo?feature=share 🗒️Access our newsletter: https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-pdufas-left-for-2q-2026 Track the countdown at BioPharmCatalyst.com 📈 #Biotech #Stocks #Trading #CING #ACHV #UNCY #BioPharmCatalyst

2 · Reply

nvy May. 21 at 5:39 PM

$ACHV Getting approval for vaping is cheaper and faster than getting approval for products that treat nicotine dependence..

2 · Reply

Market Cap	505.08M
Revenue (ttm)	0.00
Net Income (ttm)	-54.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.53

Volume	1,290,500
Avg Vol	1,487,156
Day's Range	N/A - N/A
Shares Out	102.66M
Stochastic %K	77%
Beta	2.27
Analysts	Strong Sell
Price Target	$13.62